Table 5.

Network meta‐analysis of discontinuations due to adverse events (above the diagonal) and adverse events in maintenance phases (below the diagonal).

Niraparib	1.4 (0.30, 6.3)	0.75 (0.14, 3.6)	7.2 (3, 25)
1.6 (1.1, 2.4)	Olaparib	0.55 (0.10, 2.8)	5.3 (2.1, 19)
0.85 (0.53, 1.3)	0.52 (0.33, 0.80)	Rucaparib	9.6 (3.5, 41)
3.3 (2.5, 4.4)	2 (1.5, 2.6)	3.8 (2.8, 5.6)	Placebo

Results in each cell represent the pooled RR and its 95% CrI. The estimates are located at the crossing between the column‐defining treatment and row‐defining treatment. For discontinuations due to adverse events, an RR lower than one favors the row‐defining treatment. For adverse events in maintenance phases, an RR lower than one favors the column‐defining treatment. The significant results are presented in bold.